局部治疗联合全身化疗对转移性鼻咽癌患者总生存期的影响。
Local treatment of metastases plus systemic chemotherapy on overall survival of patients with metastatic nasopharyngeal carcinoma.
机构信息
Department of Head and Neck Oncology, Department of Radiation Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Department of Radiation Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
出版信息
Head Neck. 2021 Aug;43(8):2423-2433. doi: 10.1002/hed.26706. Epub 2021 May 3.
BACKGROUND
To investigate the effect of local treatment of metastases on overall survival (OS) of patients with metastatic nasopharyngeal carcinoma (NPC).
METHODS
One hundred and forty-seven patients were included. The association between local treatment and OS was examined with propensity score matching (PSM) method.
RESULTS
In entire cohort, the median OS was significantly longer in patients with local treatment of metastases plus chemotherapy compared to those with chemotherapy alone (71.7 vs. 16.2 months; p < 0.001). In PSM cohort, similar OS benefit of patients with local treatment was observed (55.6 vs. 17.6 months; p = 0.011). The survival benefit of local treatment remained regardless of the number of metastatic lesions and metastatic sites. Patients received radiation doses of >60 Gy had longer OS than those who received less.
CONCLUSIONS
Local treatment of metastases could improve OS of patients with metastatic NPC and could be considered in their treatment in addition to chemotherapy.
背景
研究转移性鼻咽癌（NPC）患者局部治疗转移灶对总生存期（OS）的影响。
方法
共纳入 147 例患者。采用倾向评分匹配（PSM）方法分析局部治疗与 OS 的关系。
结果
在全队列中，局部治疗联合化疗的转移性 NPC 患者的中位 OS 明显长于单纯化疗患者（71.7 与 16.2 个月；p<0.001）。在 PSM 队列中，局部治疗患者也观察到了相似的 OS 获益（55.6 与 17.6 个月；p=0.011）。局部治疗的生存获益与转移灶数量和转移部位无关。接受剂量>60Gy 放疗的患者 OS 长于接受剂量<60Gy 放疗的患者。
结论
局部治疗转移灶可以改善转移性 NPC 患者的 OS，在化疗的基础上可以考虑局部治疗。
Zotero 插件